Tango reports 92% ORR in PDAC with vopimetostat + daraxonrasib combo; plans Phase 3

Tango Therapeutics, Inc.

92% ORR (11/12) in PDAC with vopimetostat + daraxonrasib; 90% 6-month PFS; 100% DCR.
100% ORR (3/3) in NSCLC with same combination; all responses confirmed.
Vopimetostat + zoldonrasib showed 52% ORR (14/27) in PDAC; 74% 6-month PFS; 96% DCR.
Combinations well tolerated; no discontinuations due to AEs; no Grade 4/5 related AEs.
Company plans Phase 3 randomized-controlled trial in front-line pancreatic cancer in 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.